Tyra Biosciences (NASDAQ:TYRA) Sets New 1-Year Low – Time to Sell?

Tyra Biosciences, Inc. (NASDAQ:TYRA)’s stock price reached a new 52-week low on Thursday . The company traded as low as $9.86 and last traded at $10.11, with a volume of 41955 shares. The stock had previously closed at $10.24.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TYRA. Wedbush reiterated an “outperform” rating and set a $30.00 target price on shares of Tyra Biosciences in a report on Friday. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Tuesday, February 18th. Finally, UBS Group assumed coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $30.83.

Tyra Biosciences Trading Up 1.1 %

The stock has a market cap of $494.39 million, a PE ratio of -6.07 and a beta of 1.09. The business’s 50-day moving average price is $12.46 and its 200-day moving average price is $16.36.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.05. As a group, analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Insider Activity at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 5,401 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total value of $74,317.76. Following the completion of the transaction, the director now directly owns 443,885 shares of the company’s stock, valued at $6,107,857.60. This trade represents a 1.20 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 21,998 shares of company stock valued at $344,818 in the last ninety days. Corporate insiders own 15.40% of the company’s stock.

Institutional Trading of Tyra Biosciences

Several large investors have recently bought and sold shares of the stock. KLP Kapitalforvaltning AS acquired a new stake in shares of Tyra Biosciences during the fourth quarter worth $31,000. US Bancorp DE purchased a new position in Tyra Biosciences in the 4th quarter worth $50,000. BNP Paribas Financial Markets acquired a new stake in Tyra Biosciences during the 4th quarter worth about $60,000. Aquatic Capital Management LLC acquired a new position in shares of Tyra Biosciences in the fourth quarter valued at about $64,000. Finally, Wells Fargo & Company MN raised its stake in shares of Tyra Biosciences by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock worth $132,000 after purchasing an additional 3,236 shares during the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.